Glenmark

Showing of 1 - 20 from 28 results
Glenmark - Total results - 28
Sunpharma launches Favipiravir tablet Fluguard to treat mild to moderate COVID-19 infections at Rs 35 per pill
science

Sunpharma launches Favipiravir tablet Fluguard to treat mild to moderate COVID-19 infections at Rs 35 per pill

Favipiravir is an antiviral drug that was originally made to treat influenza in Japan under the brand name Avigan.

Indian regulators give Glenmark approval to manufacture, sell favipiravir for ‘restricted emergency use’ in treating COVID-19 patients
India

Indian regulators give Glenmark approval to manufacture, sell favipiravir for ‘restricted emergency use’ in treating COVID-19 patients

Glenmark Pharmaceuticals Ltd has received Indian regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 infections in the country

Glenmark begins Phase 3 trials of antiviral drug Favipiravir to check efficacy on COVID-19 patients in India
science

Glenmark begins Phase 3 trials of antiviral drug Favipiravir to check efficacy on COVID-19 patients in India

Clinical trials are estimated to be completed by July-August and over 10 government and private hospitals are enrolled for the study.

Glenmark to conduct trials for potential COVID-19 drug, first company in India to receive DCGI approval; shares jump 9%
Business

Glenmark to conduct trials for potential COVID-19 drug, first company in India to receive DCGI approval; shares jump 9%

Glenmark filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients, said the BSE filing.

Glenmark Pharmaceuticals gets USFDA's final nod for Deferasirox tablets; company shares trade higher
Business

Glenmark Pharmaceuticals gets USFDA's final nod for Deferasirox tablets; company shares trade higher

The tablet is used to treat high levels of iron in the body caused by multiple blood transfusions

Q2 results paint a bleak picture for market, Adani Ports and SEZ in stable waters; all this and more on Moneycontrol Pro
Business

Q2 results paint a bleak picture for market, Adani Ports and SEZ in stable waters; all this and more on Moneycontrol Pro

Adani Ports volumes rose sharply despite depressed market conditions in global trade, which has affected India’s trade too.

How should Reserve Bank manage the rupee, stock picks from tech analysts; all this and more on Moneycontrol Pro
Business

How should Reserve Bank manage the rupee, stock picks from tech analysts; all this and more on Moneycontrol Pro

As the economic slowdown depeens, different government officials are speaking in different voices

India pharma majors Dr Reddy's, Wockhardt, and others deny allegations of conspiracy to fix prices in US
Business

India pharma majors Dr Reddy's, Wockhardt, and others deny allegations of conspiracy to fix prices in US

The generic drug makers are named in an anti-trust lawsuit in the US on allegations of engaging in a conspiracy to fix prices

Glenmark gets USFDA nod for generic blood pressure medicine
Business

Glenmark gets USFDA nod for generic blood pressure medicine

Shares of Glenmark Pharmaceuticals were trading 2.17 percent up at Rs 625.20 on BSE

Delhi HC sets aside Centre's ban on 344 fixed dose combination medicines
Business

Delhi HC sets aside Centre's ban on 344 fixed dose combination medicines

Defending its stand, the Centre had argued that the FDC medicines are "new drugs" and thus, require licence from Drugs Controller General for sale and manufacture.

FIPB clears 11 FDI proposals, refers Glenmark, Aurobindo deals to CCEA
Business

FIPB clears 11 FDI proposals, refers Glenmark, Aurobindo deals to CCEA

FIPB has cleared foreign invest in 11 entities, worth Rs 1,075.91 cr, referred proposals worth Rs 4,187 crore in firms - Glenmark and Aurobindo - to CCEA

Delhi HC allows Glenmark to make, sell antibiotic drug Linezolid
Business

Delhi HC allows Glenmark to make, sell antibiotic drug Linezolid

Delhi High Court today set aside its single judge's order restraining Mumbai-based generic drug maker Glenmark Pharmaceuticals Ltd from making and selling its antibiotic medicine Linezolid.

Indian drug makers see slowdown in US FDA approvals hitting sales for some time
Corporate

Indian drug makers see slowdown in US FDA approvals hitting sales for some time

India's $15 billion pharmaceutical industry, which has been hit by a spate of regulatory sanctions in the past year.

Glenmark gets US nod for alcohol dependence treatment drug
Business

Glenmark gets US nod for alcohol dependence treatment drug

Glenmark Generics Inc, the US-based subsidiary of Glenmark Generics Ltd (GGL), has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (USFDA) for Acamprosate Calcium Delayed Release Tablets, Glenmark Pharma said in a statement.

Sun Pharma, Glenmark get US FDA nod for Riluzole 50mg tablets
Business

Sun Pharma, Glenmark get US FDA nod for Riluzole 50mg tablets

As per the United States Food and Drug Administration (USFDA) web site, the approvals were given for generic Riluzole oral tablets in the strength of 50 mg.

Drug patent row: HC seeks Glenmark's response by May 22
Business

Drug patent row: HC seeks Glenmark's response by May 22

The Delhi HC today sought response of Glenmark Pharmaceuticals on US drug major Merck Sharp and Dohme's appeal against the single judge bench order.

Merck vs Glenmark: Another instance of MNC highhandedness
Business

Merck vs Glenmark: Another instance of MNC highhandedness

The court case is an attempt by the Big Pharma to pressure the government to not give marketing approval for generic versions of drugs that have been accorded patent in India.

Glenmark-Merck Patent row: Delhi HC refuses interim relief to Merck
Business

Glenmark-Merck Patent row: Delhi HC refuses interim relief to Merck

The Delhi High Court today refused to grant interim relief on a patent row to US pharmaceuticals major Merck Sharp and Dohme (MSD) which sought a restraint on Indian firm Glenmark manufacturing and marketing anti-diabetes drugs.

HC denies interim relief to Merck in patent case against Glenmark
Business

HC denies interim relief to Merck in patent case against Glenmark

The interim application of the multinational pharma major that Glenmark be restrained from manufacturing and selling the anti-diabetes medicines on the grounds that the salt used in the drugs were not of generic nature was denied by the court.<br /><br />